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To determine a standard combination chemotherapy for patients with advanced non-small-cell lung cancer (NSCLC), we conducted
a phase III trial of irinotecan (CPT-11) to test the hypotheses that CPT-11+cisplatin is superior to cisplatin+vindesine and that CPT-
11 monotherapy is not inferior to cisplatin+vindesine. A total of 398 patients with previously untreated NSCLC were randomised to
receive cisplatin+CPT-11 (CPT-P), cisplatin+vindesine (VDS-P) or CPT-11 alone (CPT). In the CPT-P arm, CPT-11 60mgm
 2 was
administered on days 1, 8 and 15, and cisplatin 80mgm
 2 was administered on day 1. In the VDS-P arm, cisplatin 80mgm
 2 was
administered on day 1, and vindesine 3mgm
 2 was administered on days 1, 8 and 15. In the CPT arm, CPT-11 100mgm
 2 was
administered on days 1, 8 and 15. The median survival time was 50.0 weeks for patients on CPT-P, 45.6 weeks for those on VDS-P
and 46.0 weeks for those on CPT (P¼0.115, CPT-P vs VDS-P; P¼0.089, CPT vs VDS-P), and the hazard ratio was 0.85 (95%
confidence interval (CI): 0.65–1.11) for CPT-P vs VDS-P and 0.83 (0.64–1.09) for CPT vs VDS-P. The response rate was 43.7% for
patients on CPT-P, 31.7% for those on VDS-P and 20.5% for those on CPT. Major adverse reactions were grade 4 neutropenia
observed in 37, 54 and 8% of the patients on CPT-P, VDS-P and CPT, respectively; and grades 3 and 4 diarrhoea observed in 12, 3
and 15% of the patients, respectively. CPT-P therapy produces comparable survival to VDS-P in patients with advanced NSCLC.
CPT-11 monotherapy is not inferior to VDS-P in terms of survival. The CPT-11-containing regimen is one of the most efficacious and
well tolerated in the treatment of advanced NSCLC.
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In Japan, lung cancer is the leading cause of death among all the
cancers, accounting for approximately 50000 deaths annually
(Statistics and Information Department, Minister’s secretariat,
Ministry of Health and Welfare, 2000). Non-small-cell lung cancer
(NSCLC) accounts for more than 80% of primary lung cancers.
Approximately two-thirds of NSCLC patients have advanced-stage
cancer at presentation. The median survival time (MST) of the
patients with advanced NSCLC, attained using the best available
therapy (such as cisplatin-based chemotherapy), is typically 6–10
months, and most patients die of cancer within 1–2 years of
diagnosis.
Irinotecan hydrochloride (CPT-11) is a water-soluble derivative
of camptothecin, an alkaloid originally extracted from the Chinese
tree Camptotheca acuminata. Differing from conventional anti-
tumour drugs in mechanism of action, CPT-11 produces its effect
by inhibiting the synthesis of DNA and RNA through inhibition of
DNA topoisomerase I (Kawato et al, 1991). CPT-11 has shown
strong antitumour activity as a single agent against a broad
spectrum of experimental tumours as well as against human
malignancies.
The phase I clinical trial of CPT-11, in which CPT-11 was
administered weekly, showed that the dose-limiting adverse effects
were leucopenia and diarrhoea, and the recommended dose for the
phase II monotherapy trial was 100mgm
 2week
 1 (Negoro et al,
1991). In the phase II clinical trial of CPT-11 monotherapy for
patients with untreated advanced NSCLC, the response rate was
31.9% (23 out of 72 cases) and the MST was 42 weeks (Fukuoka
et al, 1992).
In preclinical studies, CPT-11 was confirmed to act synergisti-
cally with cisplatin (CDDP) (Kudoh et al, 1993). Since CDDP is
active against NSCLC and forms part of the standard therapeutic
armamentarium employed in the treatment of NSCLC, a phase I
trial of CPT-11+CDDP was initiated in 1991 (Masuda et al, 1992).
From this trial, ‘60mgm
 2 CPT-11 on days 1, 8 and 15, and
80mgm
 2 CDDP on day 1’ were recommended as the optimal dose
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stage IIIB or IV NSCLC was started employing this dose schedule;
the response rate was 52% and the MST was 44 weeks (Masuda
et al, 1998). These results suggested that CPT-11+CDDP could
improve outcomes for patients with advanced NSCLC.
Previously, the National Cancer Institute of Canada (NCIC)
Clinical Trials Group undertook a randomised study involving
patients with NSCLC to determine whether there was a survival
advantage for those patients treated with combination chemother-
apy (vindesine (VDS)+CDDP or cyclophosphamide+doxorubi-
cin+CDDP) over best supportive care (BSC). The results of that
trial showed that the patients receiving VDS+CDDP had a
statistically significant survival advantage over patients receiving
BSC (Rapp et al, 1988). The VDS+CDDP regimen is one of the
most widely used chemotherapeutic regimens for advanced NSCLC
in Japan, and it was considered to be the most appropriate control
regimen at the time when this study was initiated.
Based on the above results, we planned a phase III trial to
compare CPT-11+CDDP and CPT-11 alone, with the control arm
of VDS+CDDP, in order to elucidate the role of CPT-11 in
advanced NSCLC.
MATERIALS AND METHODS
Eligibility criteria
Patients with histologically or cytologically confirmed and
previously untreated NSCLC were enrolled into this trial. Patients
with stage IIIB or IV cancer were eligible if they had measurable
disease and a life expectancy of at least 3 months. Additional
inclusion criteria were age (15–75 years old); a performance status
(PS) of 0–2 on the Eastern Cooperative Oncology Group (ECOG)
scale; and adequate functional indices for bone marrow (leucocyte
count between X4000 and o12000/mm
 3, platelet count
X100000/mm
 3, haemoglobin concentration X9.5gdl
 1), liver
(GOT and GPT o100IUl
 1, serum bilirubin p1.5mgdl
 1),
kidneys (serum creatinine pthe upper limit of normal) and lungs
(PaO2; at rest X8.0kPa). Patients with other concurrent malig-
nancies or a history of other malignancies, active infection,
diarrhoea (watery stool), paralytic ileus, pulmonary fibrosis,
pericardial effusion, considerable pleural effusion or ascites,
uncontrolled diabetes mellitus or symptomatic metastasis to the
brain, were excluded. Informed consent was obtained from each
patient before enrollment. Each institutional review board for
human experimentation approved the protocol of this study.
Randomisation
Eligible patients were randomised to one of the three treatment
arms by a centralised dynamic balancing method (a modified
minimisation method) using stage (IIIB/IV), PS (0–1/2) and
institution as balancing variables (Figure 1).
Treatment schedule
In the CPT-P arm, CPT-11 was given intravenously (i.v.) on days 1,
8 and 15 at a dose of 60mgm
 2, and CDDP was given i.v. on day 1
at a dose of 80mgm
 2. In the VDS-P arm, CDDP was given i.v. on
day 1 at a dose of 80mgm
 2, and VDS was given i.v. on days 1, 8
and 15 at a dose of 3mgm
 2. In the CPT arm, CPT-11 was given
i.v. on days 1, 8 and 15 at a dose of 100mgm
 2. In each arm, one
course of treatment lasted 4 weeks and each course was repeated
more than twice, until occurrence of unacceptable toxicity, disease
progression, patient’s refusal and investigator’s medical decision.
CPT-11, diluted in X500ml of normal saline, was administered
by i.v. infusion over 90min. VDS was administered as an i.v. push
with a running of 5–10ml of normal saline. CDDP was
administered i.v. as an undiluted solution and infused for a period
of 60min with more than 2600ml of hydration and a diuretic
before and after administration. To control CDDP-induced emesis,
a 5-HT3 receptor antagonist was given before CDDP administra-
tion. In the CPT-P arm, CDDP was administered after the CPT-11
infusion.
Dose modification
In all three arms, the dose of CPT-11 or VDS on day 8 or 15 was
not given if the leucocyte count was less than 3000mm
 3, platelet
count was less than 100000mm
 3, body temperature was 37.51Co r
higher, or diarrhoea was grade 1 (frequency increased to two times
or more daily, abdominal pain rated as mild or severe, or watery
stool) or higher on the ECOG scale.
In each arm, before the next course was started, the leucocyte
count had to be 4000mm
 3 or more, platelet count had to be
100000mm
 3 or more, serum creatinine concentration had to be
normal, and diarrhoea and fever should have disappeared. If there
was a delay greater than 4 weeks caused by persistent toxicity,
patients in each arm were to be withdrawn from the study.
If during the previous course, the leucocyte count had been less
than 1000mm
 3, platelet count less than 50000mm
 3 or diarrhoea
had been grade 2 (stool passage increased to four times or more
daily, stool passage at night or moderate abdominal pain, watery
stool) or higher on the ECOG scale, the dose of CPT-11 was
reduced to 50mgm
 2 in the CPT-P arm, and to 80mgm
 2 in the
CPT arm. If during the previous course the serum creatinine
concentration was more than 1.5 times the upper normal limit, the
dose of CDDP was reduced to 60mgm
 2 in the CPT-P arm and in
the VDS-P arm.
Evaluation
This trial was independently monitored and performed according
to GCP rules.
The primary end point of this study was overall survival.
Response rate, duration of response, time to disease progression
and toxicity were all secondary end points.
The stage of the disease was determined based on a complete
medical history and physical examination, routine chest radio-
graphs, fibreoptic bronchoscopy, computed tomography of the
head, chest and abdomen and bone scintigraphy. The staging
estimates were made according to the international staging system
(Mountain, 1986). Before the first course, the haemogram of each
patient was determined and serum chemistry was used to check
renal and hepatic functions, electrolytes and urinalysis. The
haemogram was assessed at least twice a week, and serum
chemistry, electrolytes, urinalysis and chest radiographs at least
once weekly. Computed tomography of the chest was repeated
monthly. Any other examination was carried out when any clinical
sign of disease progression was observed. The eligibility, evalu-
ability and response of each patient were reviewed extramurally.
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Stratification
ECOG PS
(0~1/2) 
Stage
(IIIB/IV)
Institutions
CPT-P:  CDDP    80 mg m−2   day 1
CPT-11  60 mg m−2   day 1,8,15
q 28days
VDS-P:  CDDP    80 mg m−2   day 1
VDS         3 mg m−2   day 1,8,15
q 28days
CPT:      CPT-11 100 mg m−2  day 1,8,15
q 28days
Figure 1 Study design. Patients enrolled were randomly allocated to
receive CPT-P, VDS-P or CPT, after being stratified by PS, disease stage and
institution. CPT-11¼irinotecan; CDDP¼cisplatin; VDS¼vindesine.
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336The assessment of antitumour effects and toxicity was based on the
WHO criteria (World Health Organization, 1979), but diarrhoea
was evaluated in accordance with the ECOG common toxicity
criteria (Oken et al, 1982). The overall survival was defined as the
time from randomisation to the time of death from any cause or to
last follow-up (cutoff date: 23 January 2000). The duration of each
response was defined as the time from the initial response to
disease progression. The time to disease progression was defined
as the time from the start of treatment to disease progression.
Health-related quality of life (QOL) was assessed experimentally
with a self-administered QOL questionnaire for cancer patients
treated with anticancer drugs (QOL-ACD) (Kurihara et al, 1999).
The QOL-ACD was completed at baseline, every week during
treatment and every month after treatment.
Statistical analysis
The superiority of CPT-P to VDS-P and the noninferiority of CPT
to VDS-P were evaluated in terms of survival benefit.
The sample size was calculated on the basis that MSTs were
expected to be 44, 30 and 35 weeks for the CPT-P, VDS-P and CPT
arms, respectively (Einhorn et al, 1986), and both the accrual and
follow-up intervals were 2 years.
By using the Schoenfeld and Richter equation (1982), the least
number of patients to provide the 80% power needed to confirm
the superiority of a regimen was calculated to be 115 per treatment
arm for a one-sided 2.5% significance level test. Furthermore, the
least number of deaths to provide the 80% power needed to prove
the noninferiority for the upper limit at a 95% CI for the hazard
ratio of CPT compared with VDS-P was lower than the upper
equivalence margin, 1.33, and was estimated to be 81 per treatment
arm at the one-sided 2.5% level. The significance levels for both
inferences were set at 2.5% to control the overall type I error rate,
and the one-sided statistical approach was employed to keep the
simplicity and structural consistency of the statistical inferences
for two study hypotheses. Taking ineligible patients into account,
the sample size was set at 130 per treatment arm.
Cumulative survival curves were constructed as time-to-event
plots by the Kaplan–Meier method (1958). Differences between
the curves were tested for significance using one-sided log-rank
statistics, and were estimated for noninferiority using the hazard
ratio produced by the Cox regression model (Cox and Oakes,
1984). Furthermore, Cox regression models were used to evaluate
treatment effects on survival, with adjustment for well-known
prognostic factors: stage, PS, gender, weight loss, albumin and
LDH (Albain et al, 1991; Espinosa et al, 1995; Paesmans et al, 1995;
Ray et al, 1998). Response rates and toxicities were compared
using the w
2 test. Subgroup analysis for survival was conducted by
stage.
RESULTS
Patient characteristics
From July 1995 to January 1998, 398 patients from 41 centres were
entered into this study. Of the 398 patients randomised, 18 patients
did not meet the eligibility criteria. The reasons for exclusion were:
early stage (oIIIB) in five patients, previous treatment (OK-432,
radiation therapy or surgery for local metastasis) in eight patients,
other concurrent malignancies in two patients, age (475 years) in
one patient, presence of pericardial effusion in one patient, and
leucocyte count (412000mm
 3) in one patient.
The patient characteristics at baseline are listed in Table 1. The
median age of the patients was 62–64 years and the range was 35–
75 years. A total of 62% of the patients had adenocarcinoma, 31%
had squamous cell carcinoma, 37% had stage IIIB disease and 94%
of the patients had a good performance status (PS 0–1). The three
treatment groups were well balanced for all baseline character-
istics.
Treatment administration
Three patients received no treatment (one patient in the CPT-P
arm and two patients in the CPT arm), two patients in the VDS-P
arm received vincristine (VCR) instead of VDS, one patient in the
CPT-P arm exceeded the daily dose of CPT-11 and CDDP, and one
patient in the CPT-P arm received CDDP on days 1 and 8. These
seven patients were included in the survival analysis, but excluded
from response and toxicity analysis. In all, 109 of the 126 patients
on CPT-P (87%), 97 of the 120 patients on VDS-P (81%) and 101 of
the 127 patients on CPT (80%) received more than two courses of
treatment, and 22 patients (18%) on CPT-P, 15 patients (13%) on
VDS-P and 20 patients (16%) on CPT received more than four
courses of treatment. The median number of courses administered
per patient was 3 for CPT-P and 2 for both VDS-P and CPT. The
number of treatment courses varied from one to six in each arm.
In the CPT-P, VDS-P and CPT arms, 23, 10 and 16 patients were
withdrawn from the study because of toxicities (including
duplications); 28, 44 and 51 patients because of disease progres-
sion; 37, 27 and 19 patients due to patient’s refusal; 10, 19, and 22
patients because of aggravated clinical symptom; 50, 32 and 28
patients due to investigator’s medical decision; and 6, 9 and 9
patients because of other reasons, respectively. Most patients could
repeat treatment courses every 28 days irrespective of the arm.
The number of treatment courses in which CPT-11 or VDS was
administered on days 1, 8 and 15 totaled 164 courses (50% of a
Table 1 Patient characteristics at baseline
CPT-P VDS-P CPT
Patients entered 133 133 132
Eligible patients
a 129 122 129
Gender
Male 98 98 96
Female 31 24 33
Age (years)
–49 10 19 22
50–59 36 29 30
60–69 58 51 52
70– 25 23 25
Median (range) 64 (36–75) 64 (35–75) 62 (35–75)
PS
0–1 121 115 121
28 7 8
Stage
IIIB 49 46 44
IV 80 76 85
Histology
Adenocarcinoma 78 73 84
Squamous cell
carcinoma
37 45 34
Others 14 4 11
Weight loss
No 74 67 77
Less than 5% 10 14 9
5% or more 27 30 29
Unknown 18 11 14
aPatients who were used to evaluate survival.
CPT=irinotecan; P=cisplatin; VDS=vindesine; PS=performance status.
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337total of 330 courses) for the CPT-P arm, 66 courses (24% of a total
of 279 courses) for the VDS-P arm and 182 courses (62% of a total
of 292 courses) for the CPT arm. Dose omissions on day 8 and/or
day 15 were because of diarrhoea and/or leucopenia in the CPT-P
arm and the CPT arm, and because of leucopenia in the VDS-P
arm. The median dose intensity of CDDP was the same
(20mgm
 2week
 1) for both the CPT-P and VDS-P arms. The
median dose intensity of CPT-11 was 30mgm
 2week
 1 (67% of
planned dose) for the CPT-P arm and 61.3mgm
 2week
 1 (82% of
planned dose) for the CPT arm. The median dose intensity of VDS
was 1.5mgm
 2week
 1 (67% of planned dose).
Survival
The survival curves for all eligible patients are shown in Figure 2.
The MST was 50.0 weeks for patients on CPT-P, 45.6 weeks for
those on VDS-P and 46.0 weeks for those on CPT, and the 1- and 2-
year survival rates were 46.5 and 19.4% for patients on CPT-P, 38.3
and 18.7% for those on VDS-P, and 41.8 and 21.9% for those on
CPT. The one-sided log-rank test comparing the survival of
patients who received CPT-P vs those treated with VDS-P yielded a
P-value of 0.115, and when the survival of patients treated with
CPT was compared with that of patients treated with VDS-P, the P-
value was 0.089. The hazard ratio was 0.85 (95% CI: 0.65–1.11) for
CPT-P vs VDS-P and 0.83 (95% CI: 0.64–1.09) for CPT vs VDS-P.
Subgroup analyses for survival were conducted using stage as
one of the balancing variable factors (Figure 3). Among patients
with stage IIIB disease (Figure 3A), the MST was 49.7 weeks for
those on CPT-P, 60.6 weeks for those on VDS-P and 63.3 weeks for
those on CPT. The hazard ratio was 1.24 (95% CI: 0.81–1.91, one-
sided, log-rank test: P¼0.838) for CPT-P vs VDS-P and 0.99
(95% CI: 0.63–1.56, one-sided, log-rank test: P¼0.483) for CPT vs
VDS-P.
Among patients with stage IV disease (Figure 3B), the MST was
50.0 weeks for those on CPT-P, 36.4 weeks for those on VDS-P and
42.1 weeks for those on CPT. The hazard ratio was 0.64 (95% CI:
0.46–0.89, one-sided, log-rank test: P¼0.004) for CPT-P vs VDS-P
and 0.70 (95% CI: 0.50–0.98, one-sided, log-rank test: P¼0.018)
for CPT vs VDS-P.
The Cox proportional hazards model was used to adjust for and
determine the impact of prognostic factors and treatment on
survival (Table 2). Predictive factors for improved survival
included early clinical stage, no weight loss, normal LDH, normal
albumin and better PS, each of which was significantly associated
with longer survival.
Response
Objective response data are listed in Table 3. The overall response
rate was 43.7% for patients on CPT-P, 31.7% for those on VDS-P
and 20.5% for those on CPT (two-sided, w
2 test: Po0.001).
The median duration of response for responders was 141 days
for patients on CPT-P, 121 days for those on VDS-P, and 117 days
for those on CPT (two-sided, log-rank test: P¼0.601). The median
time to progression for the patients included in the efficacy
analysis was 148 days for patients on CPT-P, 117 days for those on
VDS-P and 100 days for those on CPT (two-sided, log-rank test:
P¼0.091).
Toxicity
Major adverse reactions are listed in Table 4. Grade 4 neutropenia
was observed significantly more frequently in the VDS-P arm than
in the CPT-P and CPT arms, both of which contain CPT-11 (P o
0.001). Grade 4 thrombocytopenia was more frequent in the CPT-P
arm, but there were no thrombocytopenia-related complications.
Diarrhoea was the main nonhaematological sign of toxicity of
the regimens containing CPT-11 (CPT-P and CPT); these two
regimens were associated with a significantly higher occurrence of
grades 3 and 4 diarrhoea as compared with the VDS-P regimen
(P¼0.008). The regimens containing CDDP (CPT-P, VDS-P) were
associated with a significantly higher occurrence of grade 3
nausea/vomiting as compared with the CPT alone regimen
(P¼0.001). Peripheral neurological symptoms were observed
significantly more frequently in the VDS-P group than in the
other two groups (P o 0.001).
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Figure 2 Survival of eligible patients. Survival time was calculated from
the date patients were entered into this study. CPT¼irinotecan;
P¼cisplatin; VDS¼vindesine; n¼number of eligible patients.
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Figure 3 Survival of eligible patients: (A) stage IIIB, (B) stage IV. Survival time was calculated from the date patients were entered into this study.
CPT¼irinotecan; P¼cisplatin; VDS¼vindesine; n¼number of eligible patients.
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338Two patients died of causes whose relation to the chemotherapy
treatment could not be completely ruled out. A patient who had
received VDS-P died because of bleeding from the digestive tract
after recovery from myelosuppression. Another patient who had
received CPT died owing to subsequent infection associated with
severe diarrhoea after recovery from myelosuppression. There
were no cases of treatment-related death in the CPT-P arm.
QOL
A total of 82 patients in the CPT-P arm, 65 patients in the VDS-P
arm and 74 patients in the CPT arm completed at least one QOL
questionnaire. Compliance with the QOL questionnaire was 65%
on CPT-P, 54% on VDS-P and 58% on CPT. We could not
adequately evaluate QOL for the three arms because compliance
with the QOL questionnaire was low. Merely crude analysis
suggested no difference among the three arms in terms of QOL.
Second-line treatment
Among patients with stage IIIB disease, 45% on CPT-P, 61% on
VDS-P and 59% on CPT were subsequently treated with thoracic
irradiation.
Among patients with stage IV disease, 25% on CPT-P, 26% on
VDS-P and 40% on CPT were subsequently treated with other
chemotherapeutic regimens. In particular, seven patients on CPT-
P, nine patients on VDS-P and 10 patients on CPT were
subsequently treated with docetaxel (DTX) monotherapy or
DTX-containing regimens.
DISCUSSION
Since 1990, newer agents such as CPT-11, paclitaxel (PTX), DTX,
gemcitabine (GEM) and vinorelbine (VNB) have shown response
rates of 20% or more when used alone in previously untreated
NSCLC (Bunn and Kelly, 1998).
Except for CPT-11, all four chemotherapeutic agents have been
examined in many phase III trials in patients with advanced
NSCLC and their roles have been mostly elucidated. No trial has
been conducted, however, in order to establish the role of CPT-11
in advanced NSCLC. The present clinical trial was the first phase
III study of CPT-11 in patients with advanced NSCLC. We planned
this phase III trial in order to verify (1) whether CPT-P
significantly prolongs the survival time and (2) whether CPT
alone is not inferior in terms of the survival time, as compared
with VDS-P, one of the most commonly used chemotherapeutic
regimen that has been used in advanced NSCLC.
The first results showed that CPT-P did not significantly prolong
the survival time compared with VDS-P. Previous studies of PTX
(Belani et al, 1998; Giaccone et al, 1998; Bonomi et al, 2000), DTX
(Kubota et al, 2002), GEM (Crino et al, 1999) and VNB (Le
Chevalier et al, 1994; Martoni et al, 1998) were for comparison of a
platinum compound plus a new agent vs an old platinum-based
chemotherapy. Only the studies by Le Chevalier et al (1994) and
Kubota et al (2002) reported significant differences in terms of
survival based on the analysis scheduled in the protocol. Similar to
the present trial, there was no significant prolongation of the
survival time in other studies. There were meta-analyses of these
results that reported the superiority of the regimen of platinum
compounds plus a new agent (Baggstrom et al, 2002; Yana et al,
2002).
The second results showed that CPT-11 alone was not inferior to
VDS-P in terms of the survival time. In a study of Le Chevalier et al
(1994) that compared three groups (VNB and CDDP vs VDS and
CDDP vs VNB alone), similar to the present trial, the survival was
also similar between VNB alone and VDS-P. Toxicity on CPT alone
was mild except for slightly frequent diarrhoea. Based on these
results, chemotherapy with the new single agent may be considered
for patients who are unable to receive CDDP-containing regimens
because it can produce the similar survival to conventional
platinum-based combinations, and toxicity is relatively mild.
In the subgroup analyses according to the stage, in stage IV
patients, the MST was 50.0 weeks on CPT-P and 36.4 weeks on
VDS-P, with the CPT-P being superior to the VDS-P with respect
to survival prolongation (one-sided, log-rank test: P¼0.004). CPT-
11 alone also significantly prolonged the survival time in patients
with stage IV NSCLC compared with VDS-P. Among stage IV
patients, there was no bias in terms of background factors
including PS (the ratio of PS 0–1 patients was 96% on CPT-P, 92%
on VDS-P and 94% on CPT), gender (male ratio was 69% on CPT-
P, 79% on VDS-P and 68% on CPT) and the rate of weight loss at
baseline (the ratio of patients without weight loss was 63% on CPT-
P, 58% on VDS-P and 55% on CPT). There was no bias in the
content of second-line treatment among the treatment arms. These
are just the results of the subgroup analyses and their significance
should be shown in another research.
Table 2 Cox proportional hazards model
Variable Hazard ratio 95% CI P-value
Regimen
CPT-P/VDS-P 0.80 0.60–1.07 0.1341
CPT/VDS-P 0.88 0.66–1.16 0.3557
Stage (IV/IIIB) 1.70 1.32–2.19 0.0001
PS (2/1/0) 1.40 1.08–1.80 0.0098
Gender (male/female) 1.29 0.96–1.73 0.0922
Weight loss (X5%/o5%) 2.00 1.53–2.60 0.0001
Albumin (o4.0gdl
 1/X4.0gdl
 1) 1.53 1.17–1.98 0.0016
LDH (X400IUl
 1/o400IUl
 1) 1.54 1.17–2.04 0.0021
CI=confidence interval; CPT=irinotecan; P=cisplatin; VDS=vindesine; PS=perfor-
mance status; LDH=lactic acid dehydrogenase.
Table 3 Objective response
n CR PR NC PD NE ORR (%)
CPT-P 126 3 52 51 17 3 43.7
VDS-P 120 1 37 54 25 3 31.7
CPT 127 1 25 66 33 2 20.5
n=number of assessable patients, CR=complete response, PR=partial response,
NC=no change, PD=progressive disease, NE=not evaluable, ORR=objective
response rate, CPT=irinotecan, P=cisplatin, VDS=vindesine.
Table 4 Major adverse reactions
CPT-P VDS-P CPT
(n=126) (n=120) (n=127)
Leucopenia (grade 4) 8 (6%) 4 (3%) 2 (2%)
Neutropenia (grade 4) 46 (37%) 65 (54%) 10 (8%)
– Febrile neutropenia 13 (10%) 13 (11%) 8 (6%)
Thrombocytopenia (grade 4) 4 (3%) 1 (1%) 0 (0%)
Anaemia (grade 4) 2 (2%) 1 (1%) 1 (1%)
GOTm (grades 3 and 4) 0 (0%) 1 (1%) 0 (0%)
GPTm (grades 3 and 4) 1 (1%) 1 (1%) 0 (0%)
BUNm (grades 3 and 4) 2 (2%) 2 (2%) 0 (0%)
Creatininem (grades 3 and 4) 0 (0%) 1 (1%) 0 (0%)
Diarrhoea (grades 3 and 4) 15 (12%) 4 (3%) 19 (15%)
Nausea/vomiting (grades 3 and 4) 41 (33%) 27 (23%) 12 (9%)
Infection (grades 3 and 4) 4 (3%) 1 (1%) 6 (5%)
CPT=irinotecan; P=cisplatin; VDS=vindesine; GOT=glutamic oxaloacetic transami-
nase; GPT=glutamic pyruvic transaminase; BUN=blood urea nitrogen.
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339The results of subgroup analyses differed between stage IIIB and
stage IV patients. Between-arm differences in the ratio of patients
receiving second-line chest irradiation might, in part, lead to such
differences. In the present trial, there was no eligibility criterion to
restrict stage IIIB patients for whom thoracic irradiation was
indicated. Therefore, the possibility could not be ruled out that the
present trial included patients who were not suitable for research
purely comparing chemotherapeutic agents as in the case of this
trial. This might be one reason for different results between stages
IIIB and IV patients in the subgroup analyses. In future research,
the inclusion of stage IIIB patients should be limited to patients for
whom definitive thoracic radiation is not indicated.
Comparing survival between CPT-P and CPT-11 alone, although
this was not planned, no significant difference was shown between
the two arms (one sided, log-rank test: P¼0.587). The hazard ratio
for CPT vs CPT-P was 1.03 (95% CI: 0.79–1.34).
The overall response rate in this study was 43.7% on CPT-P,
31.7% on VDS-P and 20.5% on CPT (two-sided, w
2 test: P o 0.001).
This significant difference in the response rate did not lead to
significant differences in the survival time. Similar results have
been frequently reported in comparative studies of chemother-
apeutic agents in advanced NSCLC. Various known and unknown
prognostic factors were involved in this result. Of them, the major
factor is that complete response (CR) is obtained only in small
numbers of NSCLC patients receiving chemotherapy. In the
present trial, the CR rate was just 2.4% (three out of 126) in the
CPT-P arm, 0.8% (one out of 120) in the VDS-P arm and 0.8% (one
out of 127) in the CPT arm.
The present trial allowed including patients with PS 2. This
resulted in the inclusion of approximately 6% of PS 2 patients in
each treatment arm. In a large-scale ECOG study (E1594) by
Schiller et al (2002), the accrual of patients with PS 2 was
discontinued owing to the high rate of serious adverse events. This
fact was disclosed in May 1999 (Johnson et al, 1999), and our trial
completed patient registration before this time, so it was
impossible to exclude PS 2 patients. Inclusion of PS 2 patients
had no significant impact on the results of the present trial because
the number of such patients was small and they were distributed
evenly to the three arms according to baseline demographic
factors.
Neutropenia and neurotoxicity were more frequent in the non-
CPT-containing VDS-P arm, than in the CPT-containing CPT-P
and CPT arms. Nausea/vomiting was more frequent in the CDDP-
containing CPT-P and VDS-P arms, than in the non-CDDP-
containing CPT arm. Diarrhoea was more frequent in the CPT-
containing arm than in the VDS-P arm. In the present trial, there
were no deaths associated with the treatment in the CPT-P arm,
but one patient in the CPT arm developed diarrhoea after recovery
from myelosuppression and subsequently died from infection. In
this patient, it was not clear whether the source of infection was the
bowel or the tip of the catheter. In 10 patients treated with the
regimen containing CPT-11 who developed grade 3 or higher
infection, seven patients developed diarrhoea coincidentally with
myelosuppression, which suggested enteritis as the source of
infection. Infection was avoided in many patients by taking
proactive measures against aggravation of diarrhoea and taking
early anti-infection measures.
In conclusion, the response rate was significantly higher in
patients with CPT-P therapy compared with VDS-P, and the
survival time and toxicity were comparable, although this therapy
failed to demonstrate significant survival prolongation. Based on
these results, a large-scale randomised phase III trial comparing
CPT-P as the control regimen with three new drugs (NVB, PTX,
GEM) containing platinum-based doublets is currently underway
in Japan. CPT-11 monotherapy produced survival result that was
not inferior to that obtained with VDS-P, but produced less
toxicity. Further studies are necessary to determine the signifi-
cance of CPT-11 monotherapy in the treatment of NSCLC. This
randomised phase III trial has demonstrated that the regimen
containing CPT-11 is one of the most active and well tolerated in
the treatment of advanced NSCLC.
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